Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Clinical trial NCT04685135 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04685135
- Sponsor
- Mirati Therapeutics Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-23
- Primary completion
- 2023-12-30
- Enrollment
- 453
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.